Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes
- PMID: 17729343
- DOI: 10.1002/jmri.20989
Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes
Abstract
The vulnerability or destabilization of atherosclerotic plaques has been directly linked to plaque composition. Imaging modalities, such as magnetic resonance (MR) imaging, that allow for evaluation of plaque composition at a cellular and molecular level, could further improve the detection of vulnerable plaque and may allow for monitoring the efficacy of antiatherosclerotic therapies. In this review we focus on MR imaging strategies for the detection and evaluation of atherosclerotic plaques and their composition. We highlight recent advancements in the development of MR pulse sequences, computer image analysis, and the use of commercially available MR contrast agents, such as gadopentic acid (Gd-DTPA), for plaque characterization. We also discuss molecular imaging strategies that are currently being used to design specific imaging probes targeted to biochemical and cellular markers of atherosclerotic plaque vulnerability.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Characterization and molecular detection of atherothrombosis by magnetic resonance--potential tools for individual risk assessment and diagnostics.Ann Med. 2006;38(5):322-36. doi: 10.1080/07853890600862418. Ann Med. 2006. PMID: 16938802 Review.
-
Accurate magnetic resonance imaging of atherosclerotic plaques: change future strategies for the diagnosis and therapy of atherosclerotic disease.Med Hypotheses. 2007;68(3):656-60. doi: 10.1016/j.mehy.2006.07.044. Epub 2006 Oct 2. Med Hypotheses. 2007. PMID: 17014968
-
Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques.Mol Pharm. 2009 Nov-Dec;6(6):1903-19. doi: 10.1021/mp900106m. Mol Pharm. 2009. PMID: 19743879
-
Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits.Invest Radiol. 2008 Jan;43(1):49-55. doi: 10.1097/RLI.0b013e318155aa5a. Invest Radiol. 2008. PMID: 18097277
-
Molecular imaging by cardiovascular MR.J Cardiovasc Magn Reson. 2007;9(6):827-43. doi: 10.1080/10976640701693766. J Cardiovasc Magn Reson. 2007. PMID: 18066742 Review.
Cited by
-
Multimodal MRI for ischemic stroke: from acute therapy to preventive strategies.J Clin Neurol. 2009 Sep;5(3):107-19. doi: 10.3988/jcn.2009.5.3.107. Epub 2009 Sep 30. J Clin Neurol. 2009. PMID: 19826561 Free PMC article.
-
Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Mar-Apr;3(2):146-161. doi: 10.1002/wnan.114. Epub 2010 Oct 21. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011. PMID: 20967875 Free PMC article. Review.
-
Atherosclerotic progression attenuates the expression of Nogo-B in autopsied coronary artery: pathology and virtual histology intravascular ultrasound analysis.J Korean Med Sci. 2009 Aug;24(4):596-604. doi: 10.3346/jkms.2009.24.4.596. Epub 2009 Jul 29. J Korean Med Sci. 2009. PMID: 19654939 Free PMC article.
-
Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions.ACS Omega. 2016 Nov 30;1(5):996-1003. doi: 10.1021/acsomega.6b00210. Epub 2016 Nov 21. ACS Omega. 2016. PMID: 27917409 Free PMC article.
-
High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents.J Phys Chem B. 2009 May 7;113(18):6283-9. doi: 10.1021/jp8108286. J Phys Chem B. 2009. PMID: 19361222 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical